Lantheus completes merger with Progenics Pharmaceuticals

Lantheus Holdings completed its merger with Progenics Pharmaceuticals, an oncology company. Progenics stockholders received 0.31 shares of Lantheus common stock and a contingent value right per share.

“This combination forms an innovative company with a diversified diagnostics and therapeutics portfolio.”lantheusholdings.gcs-web.com

• 1 source
• lantheusholdings.gcs-web.comLantheus Completes Merger with ProgenicsJun 22, 2020

Summarized from public sources; check the original articles before acting on it.